陇神戎发公告，控股子公司甘肃普安制药取得甘肃省药品监督管理局核准签发的《药品上市前现场核查 及首批产品检验登记件》。药品名称为通脉口服液，药品批准文号为国药准字Z20093180，规格为10ml/ 支，有效期为18个月。该药品功能主治活血通脉，用于缺血性心脑血管疾病，动脉硬化，脑血栓，脑缺 血，冠心病，心绞痛。本次取得《药品上市前现场核查及首批产品检验登记件》，标志着通脉口服液正 式具备上市销售资质。 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-064 甘肃陇神戎发药业股份有限公司 关于控股子公司取得《药品上市前现场核查及首批产品检验 登记件》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，甘肃陇神戎发药业股份有限公司控股子公司甘肃普安制药股份有限公 司取得甘肃省药品监督管理局核准签发的《药品上市前现场核查及首批产品检验 登记件》，现将相关情况公告如下： 药品分类：中药 规格：10ml/支 有效期：18个月 药品批准文号：国药准字Z20093180 药品标准：国家药品标准YBZ03612009 一、《药品上市前现场核查及首批产品检验登记件》主要信息 关联登记号：CYZZ2400661甘 登记号：20250008 药品名称：通脉口服液 剂型：合剂 通脉口服液功能主治活血通脉，用于缺血性心脑血管疾病，动脉硬化，脑血 栓，脑缺血，冠心病，心绞痛。 三、对公司的影响 本次《药品上市前现场核查及首批产品检验登记件》的取得，标志着通脉口 服液正式具备上市销售资质，对该产品后续的生产、销售、推广等具有积极意义。 由于药品的生产和销售受市场 ...

Core Viewpoint - LongShen RongFa announced a cash dividend distribution plan, reflecting its commitment to returning value to shareholders while maintaining a stable financial position [1] Group 1: Dividend Distribution - The company will distribute a cash dividend of RMB 0.2 per 10 shares, totaling approximately RMB 6.07 million, based on a total share capital of about 303 million shares as of June 30, 2025 [1] - The record date for the dividend is September 23, 2025, and the ex-dividend date is September 24, 2025 [1] Group 2: Revenue Composition - For the first half of 2025, the revenue composition of LongShen RongFa is as follows: - Pharmaceutical sales account for 86.53% - Medical device sales account for 6.69% - Logistics and distribution account for 4.48% - Rental income from properties accounts for 0.76% - Consulting services account for 0.7% [1] Group 3: Market Capitalization - As of the report date, LongShen RongFa has a market capitalization of RMB 3 billion [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-063 2025 年半年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东会审议通过利润分配方案的情况 3.本次实施的分配方案与 2025 年第四次临时股东会审议通过的分配方案一 致。 甘肃陇神戎发药业股份有限公司 1.甘肃陇神戎发药业股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日召开的 2025 年第四次临时股东会审议通过了《2025 年半年度利润分配预案》， 公司 2025 年半年度利润分配方案为：以截至 2025 年 6 月 30 日的公司总股本 303,345,000 股为基数，向全体股东每 10 股派发现金红利人民币 0.20 元（含税）， 合计派发现金红利人民币 6,066,900.00 元，不送红股，不以资本公积转增股本。 分配预案经董事会审议后至实施权益分派的股权登记日前，公司股本如发生变动， 将按照分配总额不变的原则，对分配比例进行调整。 2.自分配方案披露至实施期间公司股本总额未发生变化。 4.本次分配方案的实施距离股东会审议通过的时 ...

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, approved during the fourth extraordinary general meeting of shareholders on September 9, 2025 [1] - The dividend is set at 0.2 yuan per 10 shares (including tax), totaling 6,066,900 yuan, based on a total share capital of 303,345,000 shares as of June 30 [1] - The record date for shareholders is September 23, 2025, and the ex-dividend date is September 24, 2025 [1] Group 2 - The cash dividends will be credited to the accounts of A-share shareholders registered by the end of trading on the record date, with the distribution handled by China Securities Depository and Clearing Corporation Limited, Shenzhen branch [1] - Investors can contact the company's securities department for inquiries regarding the dividend distribution [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-062 甘肃陇神戎发药业股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： 出席本次股东会现场会议和网络投票的股东及股东授权委托代表共 165 人， （1）现场会议召开时间：2025 年 9 月 9 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年9月9日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的时间为2025年9月9日9:15—15:00期间的任意时 间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式召开 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 电话：（0931）8260111 邮编：730030 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会法律意见书 北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会之 法律意见书 致：甘肃陇神戎发药业股份有限公司 本法律意见书仅供贵公司本次股东会相关事项的合法性之目的使用，不得用 于其他任何目的或用途。 基于此，本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》 1 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会法律意见书 和《律师事务所证券法律业务执业规则》等规定，严格履行了法定职责，遵循了 勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定的 事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误 导性陈述或者重大遗漏，并承担相应法律责任。现出具法律意见如下： 一、本次股东会的召集程序 北京德恒（兰州）律师事务所（以下 ...

Group 1 - The core point of the article indicates that Longshen Rongfa has experienced a decline in the number of shareholders for the second consecutive period, with a decrease of 2,181 shareholders, representing a 7.22% decline compared to the previous period [2] - As of the latest report, Longshen Rongfa's closing price is 9.98 yuan, reflecting a decrease of 2.06%, and the stock price has cumulatively dropped by 10.09% since the concentration of shares began, with 2 days of increase and 8 days of decrease [2] - The company's semi-annual report shows that it achieved an operating income of 496 million yuan in the first half of the year, a year-on-year decrease of 8.21%, while net profit reached 27.96 million yuan, a year-on-year increase of 27.48%, with basic earnings per share of 0.0922 yuan and a weighted average return on equity of 4.08% [2]

Core Viewpoint - The company, Longshen Rongfa, reported that as of August 29, 2025, the number of shareholders reached 28,030 [2] Summary by Relevant Sections - Shareholder Information - The total number of shareholders for the company is 28,030 as of the specified date [2]

Group 1 - The core idea of the news is the launch of ten innovative policy reform pilot projects in Gansu Province aimed at stimulating innovation and creating a better technological innovation ecosystem to support the establishment of a regional technology innovation and transformation base [2][6] - The Gansu Provincial Innovation Policy Reform Pilot Work aims to enhance the effectiveness of technological breakthroughs by organizing collaboration among enterprises, universities, and research institutions [2][4] - The Gansu High-tech Zone has developed a model focusing on collaborative development in the biopharmaceutical industry, targeting areas such as gene and cell therapy, AI+pharmaceuticals, and new vaccine development [2][3] Group 2 - The Gansu Province aims to achieve a total biopharmaceutical output value exceeding 30 billion yuan within a year, with plans to develop 3-5 generic drugs or biological products and 2-3 innovative drugs [3] - A technology investment conference was held, featuring major scientific contributions and technology demands from various sectors, including new energy, new materials, and biomedicine [4] - The Gansu Province has successfully signed contracts for 30 major technology resource introduction projects, demonstrating active engagement in technology investment and collaboration [4] Group 3 - The pilot reform of talent evaluation in Gansu Province focuses on establishing a new evaluation system based on innovation capability, effectiveness, and contribution [5] - The Gansu Provincial Science and Technology Information Research Institute has categorized scientific talents into four types, creating tailored growth paths to promote meritocracy [5] - The pilot program has shown significant results, boosting confidence in further reforms and the expansion of pilot projects across the province [6]